Real-world experience with meropenem/vaborbactam for the treatment of infections caused by ESBL-producing Enterobacterales and carbapenem-resistant Klebsiella pneumoniae.

Giusy TiseoValentina GalfoNiccolò RiccardiLorenzo Roberto SuardiManuela PogliaghiCesira GiordanoAlessandro LeonildiSimona BarniniMarco Falcone

Published in: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2024)

M/V is a promising therapeutic option against infections caused by difficult-to-treat ESBL-producing Enterobacterales and CR-Kp.

Keyphrases

klebsiella pneumoniae
escherichia coli
multidrug resistant
gram negative